Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175314
Title: | Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium |
Author: | Solà, Elsa Pose, Elisa Campion, Daniela Piano, Salvatore Roux, Olivier Simón Talero, Macarena Uschner, Frank Erhard de Wit, Koos Zaccherini, Giacomo Alessandria, Carlo Beuers, Ulrich Caraceni, Paolo Francoz, Claire Mookerjee, Rajeshwar P. Trebicka, Jonel Vargas, Víctor Serra, Miquel Torres, Ferran Montagnese, Sara Krag, Aleksander Hernaez, Rubén Korenjak, Marko Watson, Hugh Abraldes, Juan G. Kamath, Patrick S. Ginès i Gibert, Pere LiverHope consortium investigators |
Keywords: | Cirrosi hepàtica Trasplantament hepàtic Qualitat de vida Hepatic cirrhosis Hepatic transplantation Quality of life |
Issue Date: | 1-Jan-2021 |
Publisher: | Elsevier |
Abstract: | Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.jhep.2020.08.009 |
It is part of: | Journal of Hepatology, 2021, vol. 74, num. 1, p. 200-219 |
URI: | http://hdl.handle.net/2445/175314 |
Related resource: | https://doi.org/10.1016/j.jhep.2020.08.009 |
ISSN: | 0168-8278 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
705293.pdf | 566.67 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License